Top Institutional Investors

Verdad Advisers, LP — 13F Holdings & Portfolio

CIK 1812822 · latest 13F-HR filed 2026-08-14

Backtest portfolio

Verdad Advisers, LP manages $104.4M in 13F-reported U.S. long-equity assets across 210 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are AAPL (2.06%), BLTE (2.03%), ACAD (2.00%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 97 new positions and exited 66; 62 existing positions rose in reported value and 45 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$104.4M

Long-equity book

Holdings
210

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+97 / −66 / ↑62 / ↓45

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26
AAPL2.1% · newBLTE2.0% · -0%ACAD2.0% · +21%CMCSA2.0% · +104%CLDT1.8% · 0%TENX1.7% · +29%SLDE1.7% · +197%ZYME1.7% · -19%AMN1.6% · +4%XFOR1.6% · newVSNT1.5% · +129%NTCT1.4% · +125%WHWK1.3% · +161%JNJ1.3% · -1%CTNM1.3% · -6%JBIO1.2% · newCSCO1.2% · newNRIX1.1% · -41%TARA1.1% · newBLMN1.1% · +30%TYRA1.1% · newPARR1.1% · -11%EWTX1.1% · +109%GOOGL1.0% · newCRI1.0% · 0%VERA1.0% · +131%NUVL1.0% · newDNTH0.9% · +16%ACRS0.9% · -11%OPY0.9% · +154%VZ0.8% · newMYE0.8% · newELVN0.8% · newUVE0.8% · newBNY0.8% · newCNXN0.8% · newAII0.8% · +3%AMAT0.8% · -62%AHCO0.7% · -21%ALL0.7% · newCLDX0.7% · newRVMD0.7% · -81%HRTG0.7% · +8%SNX0.7% · +92%MOV0.7% · +75%SND0.7% · +16%VRDN0.7% · +24%DSGN0.7% · -48%MMI0.7% · +41%MATV0.7% · newSNEX0.6% · -18%CTMX0.6% · +484%NLOP0.6% · +146%GERN0.6% · newOOMA0.6% · +70%RCKY0.6% · +2%JANX0.6% · newZM0.6% · -67%GPCR0.6% · 0%AVTX0.6% · new

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 18.1%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 11, 2026.

Assets Under Management
$1.18B
Discretionary
$1.18B
Employees
8
Accounts
33
Address
695 ATLANTIC AVE.
4TH FLOOR
BOSTON, MA 02111
Phone
(202) 251-6707
Website
Name Title / Status Ownership Type
RASMUSSEN, DANIEL ControlLIMITED PARTNER, MANAGING PARTNER, CCO
since Mar 2014
50–75%Individual
VERDAD ASSET MANAGEMENT, LLC ControlGENERAL PARTNER
since Mar 2014
Less than 5%Domestic Entity
DANIEL RASMUSSEN Control
Indirect owner via VERDAD ASSET MANAGEMENT, LLC
MEMBER & MANAGER
since Mar 2014
General partner, trustee or managerDomestic Entity
Ownership & leadership changes · 1 filing with changes since Mar 30, 2019

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Apr 26, 2019 filing
  • ChangedRASMUSSEN, DANIEL · title LIMITED PARTNER → LIMITED PARTNER, MANAGING PARTNER, CCO
Mar 30, 2019 filing (earliest on record)
  • ListedDANIEL RASMUSSEN · MEMBER & MANAGER · General partner, trustee or manager · indirect via VERDAD ASSET MANAGEMENT, LLC · control person
  • ListedRASMUSSEN, DANIEL · LIMITED PARTNER · 50–75% · control person
  • ListedVERDAD ASSET MANAGEMENT, LLC · GENERAL PARTNER · Less than 5% · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Verdad Advisers, LP Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 APPLE INC AAPL 037833100 $2.2M 2.06% 7,445 SH
2 BELITE BIO INC BLTE 07782B104 $2.1M 2.03% 13,758 SH
3 ACADIA PHARMACEUTICALS INC ACAD 004225108 $2.1M 2.00% 82,629 SH
4 COMCAST CORP NEW CMCSA 20030N101 $2.1M 1.99% 84,569 SH
5 CHATHAM LODGING TR CLDT 16208T102 $1.9M 1.77% 140,000 SH
6 TENAX THERAPEUTICS INC TENX 88032L605 $1.8M 1.72% 123,174 SH
7 SLIDE INS HLDGS INC SLDE 831349105 $1.8M 1.69% 91,070 SH
8 ZYMEWORKS INC ZYME 98985Y108 $1.7M 1.67% 66,688 SH
9 AMN HEALTHCARE SVCS INC AMN 001744101 $1.7M 1.61% 51,906 SH
10 X4 PHARMACEUTICALS INC XFOR 98420X202 $1.6M 1.57% 352,093 SH
11 VERSANT MEDIA GROUP INC VSNT 925283103 $1.6M 1.50% 43,503 SH
12 NETSCOUT SYS INC NTCT 64115T104 $1.4M 1.38% 33,128 SH
13 WHITEHAWK THERAPEUTICS INC WHWK 00032Q104 $1.4M 1.32% 301,483 SH
14 JOHNSON & JOHNSON JNJ 478160104 $1.4M 1.31% 5,384 SH
15 CONTINEUM THERAPEUTICS INC CTNM 21217B100 $1.3M 1.27% 81,014 SH
16 JADE BIOSCIENCES INC JBIO 008064206 $1.3M 1.20% 56,384 SH
17 CISCO SYS INC CSCO 17275R102 $1.2M 1.16% 10,307 SH
18 NURIX THERAPEUTICS INC NRIX 67080M103 $1.2M 1.15% 49,511 SH
19 PROTARA THERAPEUTICS INC TARA 74365U107 $1.2M 1.14% 312,249 SH
20 BLOOMIN BRANDS INC BLMN 094235108 $1.2M 1.14% 130,000 SH
21 TYRA BIOSCIENCES INC TYRA 90240B106 $1.1M 1.10% 36,003 SH
22 PAR PAC HOLDINGS INC PARR 69888T207 $1.1M 1.07% 20,000 SH
23 EDGEWISE THERAPEUTICS INC EWTX 28036F105 $1.1M 1.06% 27,234 SH
24 ALPHABET INC GOOGL 02079K305 $1.0M 0.99% 2,900 SH
25 CARTERS INC CRI 146229109 $1.0M 0.99% 25,000 SH
26 VERA THERAPEUTICS INC VERA 92337R101 $1.0M 0.97% 23,487 SH
27 NUVALENT INC NUVL 670703107 $1.0M 0.96% 8,104 SH
28 DIANTHUS THERAPEUTICS INC DNTH 252828108 $980.8K 0.94% 10,062 SH
29 ACLARIS THERAPEUTICS INC ACRS 00461U105 $927.2K 0.89% 175,272 SH
30 OPPENHEIMER HLDGS INC OPY 683797104 $915.3K 0.88% 8,673 SH
31 VERIZON COMMUNICATIONS INC VZ 92343V104 $886.5K 0.85% 20,938 SH
32 MYERS INDS INC MYE 628464109 $865.1K 0.83% 24,500 SH
33 ENLIVEN THERAPEUTICS INC ELVN 29337E102 $860.6K 0.82% 16,957 SH
34 UNIVERSAL INS HLDGS INC UVE 91359V107 $850.3K 0.81% 20,558 SH
35 BANK OF NY MELLON CORP BNY 064058100 $831.2K 0.80% 5,748 SH
36 PC CONNECTION INC CNXN 69318J100 $809.0K 0.77% 11,084 SH
37 AMERICAN INTEGRITY INS GROUP AII 026948109 $794.2K 0.76% 42,178 SH
38 APPLIED MATLS INC AMAT 038222105 $787.3K 0.75% 1,089 SH
39 ADAPTHEALTH CORP AHCO 00653Q102 $781.5K 0.75% 75,000 SH
40 ALLSTATE CORP ALL 020002101 $780.2K 0.75% 3,279 SH
41 CELLDEX THERAPEUTICS INC NEW CLDX 15117B202 $770.4K 0.74% 20,704 SH
42 REVOLUTION MEDICINES INC RVMD 76155X100 $759.0K 0.73% 4,053 SH
43 HERITAGE INSURANCE HLDGS INC HRTG 42727J102 $745.2K 0.71% 28,575 SH
44 TD SYNNEX CORPORATION SNX 87162W100 $743.2K 0.71% 2,780 SH
45 MOVADO GROUP INC MOV 624580106 $737.5K 0.71% 18,762 SH
46 SMART SAND INC SND 83191H107 $714.8K 0.68% 142,684 SH
47 VIRIDIAN THERAPEUTICS INC VRDN 92790C104 $711.3K 0.68% 38,722 SH
48 DESIGN THERAPEUTICS INC DSGN 25056L103 $688.1K 0.66% 47,557 SH
49 MARCUS & MILLICHAP INC MMI 566324109 $684.9K 0.66% 21,972 SH
50 MATIV HOLDINGS INC MATV 808541106 $681.3K 0.65% 90,000 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $104.4M 210 0001420506-26-001697
2026-03-31 2026-05-15 $88.8M 179 0001420506-26-001092
2025-12-31 2026-02-17 $87.4M 104 0001420506-26-000495
2024-09-30 2024-11-14 $74.9M 93 0001420506-24-002479
Filer Information
Address
695 ATLANTIC AVENUE
4TH FLOOR
BOSTON, MA 02111
Phone
(202) 251-6707
Filing Manager
Verdad Advisers, LP
BOSTON, MA
Signatory
DANIEL RASMUSSEN
Managing Partner